These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

566 related items for PubMed ID: 20232023

  • 1. [Evaluation of pharmacodynamic target attainment with vancomycin treatment of bacteremia due to Staphylococcus aureus methicillin resistant].
    Lepe JA, Gil-Navarro MV, Santos-Rubio MD, Bautista J, Aznar J.
    Rev Esp Quimioter; 2010 Mar; 23(1):43-7. PubMed ID: 20232023
    [Abstract] [Full Text] [Related]

  • 2. Relationships between vancomycin minimum inhibitory concentration, dosing strategies, and outcomes in methicillin-resistant Staphylococcus aureus bacteremia.
    Clemens EC, Chan JD, Lynch JB, Dellit TH.
    Diagn Microbiol Infect Dis; 2011 Dec; 71(4):408-14. PubMed ID: 21924852
    [Abstract] [Full Text] [Related]

  • 3. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
    Khatib R, Jose J, Musta A, Sharma M, Fakih MG, Johnson LB, Riederer K, Shemes S.
    J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
    [Abstract] [Full Text] [Related]

  • 4. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.
    Kullar R, Davis SL, Levine DP, Rybak MJ.
    Clin Infect Dis; 2011 Apr 15; 52(8):975-81. PubMed ID: 21460309
    [Abstract] [Full Text] [Related]

  • 5. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
    Jung Y, Song KH, Cho Je, Kim HS, Kim NH, Kim TS, Choe PG, Chung JY, Park WB, Bang JH, Kim ES, Park KU, Park SW, Kim HB, Kim NJ, Oh MD.
    Int J Antimicrob Agents; 2014 Feb 15; 43(2):179-83. PubMed ID: 24315788
    [Abstract] [Full Text] [Related]

  • 6. Methicillin-resistant Staphylococcus aureus bacteremia: epidemiology, outcome, and laboratory characteristics in a tertiary referral center in the UK.
    Lewis T, Chaudhry R, Nightingale P, Lambert P, Das I.
    Int J Infect Dis; 2011 Feb 15; 15(2):e131-5. PubMed ID: 21134776
    [Abstract] [Full Text] [Related]

  • 7. A stewardship program's retrospective evaluation of vancomycin AUC24/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
    Gawronski KM, Goff DA, Brown J, Khadem TM, Bauer KA.
    Clin Ther; 2013 Jun 15; 35(6):772-9. PubMed ID: 23795575
    [Abstract] [Full Text] [Related]

  • 8. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia.
    Walraven CJ, North MS, Marr-Lyon L, Deming P, Sakoulas G, Mercier RC.
    J Antimicrob Chemother; 2011 Oct 15; 66(10):2386-92. PubMed ID: 21775337
    [Abstract] [Full Text] [Related]

  • 9. [Persistent bacteremia due to methicillin-resistant Staphylococcus aureus. A result of inadequate treatment].
    Parra-Ruiz J, Tomas-Jiménez C, Muñoz-Medina L, Hernández-Quero J.
    Enferm Infecc Microbiol Clin; 2009 Jun 15; 27(6):372-3. PubMed ID: 19339080
    [No Abstract] [Full Text] [Related]

  • 10. Impact of vancomycin MIC creep on patients with methicillin-resistant Staphylococcus aureus bacteremia.
    Yeh YC, Yeh KM, Lin TY, Chiu SK, Yang YS, Wang YC, Lin JC.
    J Microbiol Immunol Infect; 2012 Jun 15; 45(3):214-20. PubMed ID: 22571999
    [Abstract] [Full Text] [Related]

  • 11. High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylococcus aureus bacteraemia.
    Wi YM, Kim JM, Joo EJ, Ha YE, Kang CI, Ko KS, Chung DR, Song JH, Peck KR.
    Int J Antimicrob Agents; 2012 Aug 15; 40(2):108-13. PubMed ID: 22633565
    [Abstract] [Full Text] [Related]

  • 12. Clinical, microbiologic, and genetic determinants of persistent methicillin-resistant Staphylococcus aureus bacteremia.
    Neuner EA, Casabar E, Reichley R, McKinnon PS.
    Diagn Microbiol Infect Dis; 2010 Jul 15; 67(3):228-33. PubMed ID: 20542203
    [Abstract] [Full Text] [Related]

  • 13. Predicting high vancomycin minimum inhibitory concentration isolate infection among patients with community-onset methicillin-resistant Staphylococcus aureus bacteraemia.
    Chen SY, Hsueh PR, Chiang WC, Huang EP, Lin CF, Chang CH, Chen SC, Chen WJ, Chang SC, Lai MS, Chie WC.
    J Infect; 2014 Sep 15; 69(3):259-65. PubMed ID: 24797078
    [Abstract] [Full Text] [Related]

  • 14. Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin.
    Yoon YK, Kim JY, Park DW, Sohn JW, Kim MJ.
    J Antimicrob Chemother; 2010 May 15; 65(5):1015-8. PubMed ID: 20200036
    [Abstract] [Full Text] [Related]

  • 15. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections.
    Hsu DI, Hidayat LK, Quist R, Hindler J, Karlsson A, Yusof A, Wong-Beringer A.
    Int J Antimicrob Agents; 2008 Nov 15; 32(5):378-85. PubMed ID: 18701261
    [Abstract] [Full Text] [Related]

  • 16. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study.
    Murray KP, Zhao JJ, Davis SL, Kullar R, Kaye KS, Lephart P, Rybak MJ.
    Clin Infect Dis; 2013 Jun 15; 56(11):1562-9. PubMed ID: 23449272
    [Abstract] [Full Text] [Related]

  • 17. Daptomycin therapy failure in an adolescent with methicillin-resistant Staphylococcus aureus bacteremia.
    Jacobson LM, Milstone AM, Zenilman J, Carroll KC, Arav-Boger R.
    Pediatr Infect Dis J; 2009 May 15; 28(5):445-7. PubMed ID: 19295462
    [Abstract] [Full Text] [Related]

  • 18. Is high vancomycin minimum inhibitory concentration a good marker to predict the outcome of methicillin-resistant Staphylococcus aureus bacteremia?
    Lalueza A, Chaves F, San Juan R, Daskalaki M, Otero JR, Aguado JM.
    J Infect Dis; 2010 Jan 15; 201(2):311-2; author reply 312-3. PubMed ID: 20034343
    [No Abstract] [Full Text] [Related]

  • 19. Is there a clinical association of vancomycin MIC creep, agr group II locus, and treatment failure in MRSA bacteremia?
    de Sanctis JT, Swami A, Sawarynski K, Gerasymchuk L, Powell K, Robinson-Dunn B, Carpenter CF, Sims MD.
    Diagn Mol Pathol; 2011 Sep 15; 20(3):184-8. PubMed ID: 21817905
    [Abstract] [Full Text] [Related]

  • 20. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia.
    Song KH, Kim HB, Kim HS, Lee MJ, Jung Y, Kim G, Hwang JH, Kim NH, Kim M, Kim CJ, Choe PG, Chung JY, Park WB, Kim ES, Park KU, Kim NJ, Kim EC, Oh MD.
    Int J Antimicrob Agents; 2015 Dec 15; 46(6):689-95. PubMed ID: 26555059
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.